Zura Bio Ltd (OQ:ZURA)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 4225 Executive Square, Suite - 600
SAN DIEGO CA 92037
Tel: N/A
Website: https://zurabio.com
IR: See website
<
Key People
Robert Lisicki
Chief Executive Officer, Director
Verender S. Badial
Interim Chief Financial Officer
Theresa Lowry
Chief Human Resource Officer
Gary Whale
Chief Technology Officer
Michael Howell
Chief Scientific Officer, Head of Translational Medicine
Kiran Nistala
Chief Medical Officer, Head of Development
Kim Davis
Chief Legal Officer and Secretary
   
Business Overview
Zura Bio Limited is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), ZB-168, and torudokimab (ZB-880) with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other novel indications with unmet needs. Tibulizumab (ZB-106) is an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of TALTZ (ixekizumab) and tabalumab that neutralizes IL-17A and BAFF. ZB-168 is a fully human, high affinity monoclonal antibody that binds and neutralizes the IL-7 receptor chain (IL-7R) alpha. Torudokimab (ZB-880) is a fully human, high affinity monoclonal antibody that neutralizes IL-33, preventing ST2-dependent and ST2-independent inflammation.
Financial Overview
For the three months ended 31 March 2024, Zura Bio Ltd revenues was not reported. Net loss applicable to common stockholders decreased 93% to $730K. Lower net loss reflects Stock-based Compensation in R&D decrease of 80% to $433K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$2.76 to -$0.02.
Employees: 14 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $175.52M as of Mar 31, 2024
Annual revenue (TTM): $0.00M as of Mar 31, 2024
EBITDA (TTM): -$63.30M as of Mar 31, 2024
Net annual income (TTM): -$60.18M as of Mar 31, 2024
Free cash flow (TTM): -$24.04M as of Mar 31, 2024
Net Debt Last Fiscal Year: N/A
Shares outstanding: 63,683,806 as of May 9, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.